Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...
All Penny Stocks (English) on MSN4d
Biotech Rips On Topline AnalysisA biotech company is turning heads so far during Tuesday’s session after it shared topline analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback